On March 26, 2025 Innovent Biologics reported annual results announcement for the year ended 31 December 2024 (Filing, 3 mnth, DEC 31, Innovent Biologics, 2024, MAR 26, 2025, View Source [SID1234651499]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 26, 2025 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, reported that clinical data on neratinib will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2025. The AACR (Free AACR Whitepaper) Annual Meeting will be held at the McCormick Place in Chicago, Illinois, from April 25–30, 2025 (Press release, Puma Biotechnology, MAR 26, 2025, View Source [SID1234651498]). The title of the poster that will be presented is now available on the AACR (Free AACR Whitepaper) Annual Meeting website at View Source!/20273/presentation/10447. The full poster will be available on the Puma website concurrent with the live presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Session: First-in-Human Phase I Clinical Trials 1

Abstract CT071: Title: Phase I trial of trastuzumab deruxtecan in combination with neratinib in solid tumors with HER2 alterations (NCI 10495)
Authors: Andrew A. Davis, Haeseong Park, Ecaterina E. Dumbrava, Nataliya V. Uboha, Aparna Kalyan, Farshid Dayyani, Mili Arora, Miguel A. Villalona-Calero, Haider S. Mahdi, Reema A. Patel, Floor Backes, Jessica Porzel, Whitney L. Hensing, Cheryl Pickett, Cynthia X. Ma, Ron Bose
Presenter: Andrew Davis, MD, Washington University School of Medicine
Date/Time: April 28, 2025, 2:00–5:00 p.m. CT

On March 26, 2025 SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, reported it will present new data from two of its antibody-drug conjugate (ADC) programs for the treatment of solid tumors, showcasing advancements in its innovative pipeline (Press release, SOTIO, MAR 26, 2025, View Source [SID1234651497]). The presentations will take place at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in Chicago, IL from April 25-30, 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SOT106 is being developed for the treatment of patients with sarcomas and other LRRC15-positive tumors. The oral presentation at AACR (Free AACR Whitepaper) will feature new preclinical in vitro and in vivo data. SOT106 targets leucine-rich repeat containing protein 15 (LRRC15), a protein that is commonly overexpressed in mesenchymal malignancies.

SOT109 is being developed for the treatment of colorectal cancer and other gastrointestinal cancers. It targets cadherin-17 (CDH17), a protein homogenously overexpressed in more than 90% of colorectal cancers. The poster presentation at AACR (Free AACR Whitepaper) will showcase preclinical data on the efficacy and safety of SOT109 across various models.

Presentation details are as follows:

Oral Presentation Title: "SOT106, a novel best-in-class antibody-drug conjugate targeting LRRC15, to treat sarcomas and other advanced solid cancers"
Abstract Number: 1164
Session: Experimental and Molecular Therapeutics / Antibody-Based Cancer Therapeutic Agents
Presenting Author: Michaela Fojtu
Date & Time: April 27, 2025, 3:00 p.m. – 5:00 p.m. CT

Poster Title: "Preclinical safety and efficacy of SOT109, an antibody-drug conjugate targeting Cadherin 17 (CDH17) for the treatment of colorectal and other gastrointestinal tract tumors"
Abstract Number: 5469
Session: Experimental and Molecular Therapeutics
Presenting Author: Nataliia Kalynovska
Date & Time: April 29, 2025, 2:00 p.m. – 5:00 p.m. CT
Location: Poster Section 15, Board Number 27

Presentation materials will be made available here after presentations at AACR (Free AACR Whitepaper) conclude.

On March 26, 2025 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") reported that an abstract regarding IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, has been selected for the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2025, taking place April 25-30 in Chicago, Illinois (Press release, Innate Pharma, MAR 26, 2025, View Source [SID1234651496]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, Jonathan Dickinson, CEO of Innate Parma, will present in a showcase session at the AACR (Free AACR Whitepaper) Oncology Industry Partnering Event, to give an update on Innate’s pipeline and strategy.

Presentation details

AACR 2025 ANNUAL MEETING

IPH4502, a differentiated Nectin-4 exatecan antibody-drug conjugate

Abstract Number: 5443

Session Type: Poster session

Session Category: Experimental and Molecular Therapeutics

Session Title: Antibody-Based Cancer Therapeutics 3

Session Date/Time: Tuesday Apr 29, 2025 2:00 PM – 5:00 PM

More information can be found on the AACR (Free AACR Whitepaper) website.

AACR ONCOLOGY INDUSTRY PARTNERING EVENT

Showcase Session 2 | W192

Presenter: Jonathan Dickinson, Chief Executive Officer

Date and Time: Thursday Apr 24, 2025 4:50 PM

Location: McCormick Place Convention Center West Building, Chicago, Illinois

More information can be found on the AACR (Free AACR Whitepaper) Oncology Industry Partnering Event website.

About IPH4502

IPH4502 is a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) conjugated to exatecan targeting Nectin-4, a cell adhesion molecule that is overexpressed in several types of solid tumors, such as urothelial carcinoma, breast cancer, non-small cell lung cancer or gastro-intestinal tract cancer.

IPH4502 is currently investigated in a Phase 1 trial in advanced solid tumors. The Phase 1 trial includes a dose escalation part 1 and a dose optimization part 2 and will assess the safety, tolerability, and preliminary efficacy of IPH4502 in different solid tumors known to express Nectin-4, including but not limited to urothelial carcinoma, non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers. The study plans to enroll approximately 105 patients.

In preclinical models, IPH4502 demonstrates strong bystander killing effect, and efficient internalization, enabling a potent anti-tumor activity in models with various Nectin-4 expression levels. Additionally, IPH4502 shows efficacy in models resistant to MMAE-ADC. These results support its potential for development beyond UC and in cancer patients treated with MMAE-based ADCs.

On March 26, 2025 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) reported that data from preclinical studies of the Company’s internally discovered and developed next-generation, investigational oncology therapies, ZL-6201, an LRRC15 antibody-drug conjugate (ADC) for the treatment of sarcoma, and ZL-1222, a PD-1 targeted IL-12 immunocytokine for cancer immunotherapy, will be presented during poster sessions at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2025 taking place April 25-30, 2025 in Chicago, Illinois (Press release, Zai Laboratory, MAR 26, 2025, View Source [SID1234651495]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Aligned with our strategy for our internally developed global oncology pipeline, ZL-6201 and ZL-1222 are promising investigational compounds with the potential to address multiple cancer types, including several that remain challenging to treat with current standard-of-care therapies," said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab.

LRRC15 is a type I transmembrane protein and an appealing target for cancer therapy because it is overexpressed in various mesenchymal tumors, such as sarcoma, glioblastoma and melanoma. Zai Lab is evaluating ZL-6201 as a potential first-in-class LRRC15 ADC targeting multiple solid tumors.

Interleukin-12 treatments have demonstrated potential to offer therapeutic benefit across a range of cancer types; however, narrow therapeutic windows and toxicity concerns have limited the benefit of this therapeutic class. Zai Lab is evaluating ZL-1222 as a potential next-generation PD-1-targeted IL-12 immunocytokine for cancer immunotherapy across a variety of indications, potentially combining potent antitumor activity with improved systemic safety.

Details regarding the Zai Lab poster presentations at AACR (Free AACR Whitepaper) 2025 are as follows:

Title: Discovery and characterization of a novel LRRC15-targeting antibody-drug conjugate (ADC) for the treatment of solid tumors
Presenter: Bing Wan, Ph.D., Executive Director, Biology, Zai Lab
Session Title: New and Emerging Cancer Drug Targets
Date/Time: Tuesday, April 29, 2025, from 9:00 a.m. – 12:00 p.m. CT
Location: McCormick Place Convention Center, Poster Section 17
Poster Board Number: 23
Published Abstract Number: 4266

Title: Cis-delivery of a potency-reduced IL-12 via an anti-PD-1 single-chain antibody exhibits potent anti-tumor activity
Presenter: Linda Liu, Ph.D., Senior Vice President, Biologics Discovery, Zai Lab
Session Title: Late-Breaking Research: Clinical Research 1
Date/Time: Monday, April 28, 2025, from 2:00 p.m. – 5:00 p.m. CT
Location: McCormick Place Convention Center, Poster Section 53
Poster Board Number: 1
Publish Abstract Number: LB2024